Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound MEDLINE
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
(antispasmodic)
48,232 results
  • GeneReviews®: Spastic Paraplegia 4 [BOOK]
  • BOOKUniversity of Washington, Seattle: Seattle (WA)
  • Adam MP, Ardinger HH, … Amemiya AParodi L, Rydning SL, … Durr A
  • Spastic paraplegia 4 (SPG4; also known as SPAST-HSP) is characterized by insidiously progressive bilateral lower-limb gait spasticity. More than 50% of affected individuals have some weakness in the …
  • Mometasone or Tiotropium in Mild Asthma with a Low Sputum Eosinophil Level. [Randomized Controlled Trial]
  • NEJMN Engl J Med 2019 05 23; 380(21):2009-2019
  • Lazarus SC, Krishnan JA, … National Heart, Lung, and Blood Institute AsthmaNet
  • CONCLUSIONS: The majority of patients with mild, persistent asthma had a low sputum eosinophil level and had no significant difference in their response to either mometasone or tiotropium as compared with placebo. These data provide equipoise for a clinically directive trial to compare an inhaled glucocorticoid with other treatments in patients with a low eosinophil level. (Funded by the National Heart, Lung, and Blood Institute; SIENA ClinicalTrials.gov number, NCT02066298.).
  • Baclofen Unusual Response In Spinal Cord Injury Patients. [Case Reports]
  • JAJ Ayub Med Coll Abbottabad 2019 Apr-Jun; 31(2):269-271
  • Ullah S, Edrees M, Alhabtar AM
  • Spasticity after spinal cord injury is a major problem that can limit the effectiveness of rehabilitation programs. Oral baclofen is more frequently used in treating spasticity than other antispasmod…
  • Progress in Pharmacological and Surgical Management of Tourette Syndrome and Other Chronic Tic Disorders. [Review]
  • NNeurologist 2019; 24(3):93-108
  • Pandey S, Dash D
  • CONCLUSIONS: Both typical and atypical antipsychotic agents are mainstays of pharmacological treatment of TS and other chronic tic disorder patients; however, their use is limited by serious side effects considering their potential of dopamine blockade. Because of the phenotypic variability, no medication has proven effective for all persons with TS and other chronic tic disorders. Botulinum toxin has emerged as a good therapeutic option, especially for focal and dystonic tics. But, their uses are limited by lack of sufficient evidence and high cost. Surgical treatment is considered in medically refractory and severely disabled tics patients. Deep brain stimulation has replaced lesional surgeries; however, there is uncertainty regarding the selection of patients and target of stimulation.
New Search Next